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Marrow adipose tissue (MAT) is an endocrine organ with the potential to influence skeletal remodeling and hematopoiesis. Pathologic MAT expansion has been studied in the
context of severe metabolic challenge, including caloric restriction, high fat diet feeding,
and leptin deficiency. However, the rapid change in peripheral fat and glucose metabolism associated with these models impedes our ability to examine which metabolic
parameters precede or coincide with MAT expansion. Microfibril-associated glycoprotein-1 (MAGP1) is a matricellular protein that influences cellular processes by tethering
signaling molecules to extracellular matrix structures. MAGP1-deficient (Mfap2−/−) mice
display a progressive excess adiposity phenotype, which precedes insulin resistance
and occurs without changes in caloric intake or ambulation. Mfap2−/− mice were, therefore, used as a model to associate parameters of metabolic disease, bone remodeling,
and hematopoiesis with MAT expansion. Marrow adiposity was normal in Mfap2−/− mice
until 6 months of age; however, by 10 months, marrow fat volume had increased fivefold relative to wild-type control at the same age. Increased gonadal fat pad mass and
hyperglycemia were detectable in Mfap2−/− mice by 2 months, but peaked by 6 months.
The development of insulin resistance coincided with MAT expansion. Longitudinal
characterization of bone mass demonstrated a disconnection in MAT volume and bone
volume. Specifically, Mfap2−/− mice had reduced trabecular bone volume by 2 months,
but this phenotype did not progress with age or MAT expansion. Interestingly, MAT
expansion in the 10-month-old Mfap2−/− mice was associated with modest alterations in
basal hematopoiesis, including a shift from granulopoiesis to B lymphopoiesis. Together,
these findings indicate MAT expansion is coincident with insulin resistance, but not
excess peripheral adiposity or hyperglycemia in Mfap2−/− mice; and substantial MAT
accumulation does not necessitate a proportional decrease in either bone mass or bone
marrow cellularity.
Keywords: marrow adipose tissue, obesity, insulin resistance, bone remodeling, hematopoiesis, microfibrilassociated glycoprotein-1

Abbreviations: ECM, extracellular matrix; MAT, marrow adipose tissue; MAGP1, microfibril-associated glycoprotein-1.
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INTRODUCTION

MATERIALS AND METHODS

Adipose tissue exists in multiple variations, the most extensively
studied being: brown, white, and beige. Brown adipocytes
specialize in utilizing energy to produce heat (thermogenesis),
white adipocytes are energy-storing reservoirs, and beige
adipocytes principally store lipids but can be stimulated to
transdifferentiate into a “brown-like” state (1). Less studied is a
fourth lipid storing depot, located within the skeleton, marrow
adipose tissue (MAT). These skeleton-associated adipocytes
arise from a unique progenitor (2) and occupy approximately
70% of the marrow space within adult human bones (3).
There is an evidence that MAT adipocytes exist in two forms:
regulated marrow adipocytes (rMATs) that respond in size
and number to physiological challenge, and the constitutive
marrow adipocytes (cMATs) that persist despite challenge (4).
Marrow adipocytes are not inert space-filling cells. Rather,
the ability to produce leptin and adiponectin classifies them
as an endocrine organ (5, 6). These cells also release fatty
acids via lipolysis, suggesting that they may fuel local cellular
processes (7).
Pathologic MAT expansion, as a consequence of metabolic
dysfunction, has been studied in several contexts, including
caloric restriction, high fat diet feeding, and leptin deficiency
(6, 8–10). Unfortunately, the rapid change in peripheral fat and
glucose metabolism associated with these models impedes our
ability to determine which metabolic parameters precede or
coincide with MAT expansion. The objective of this study was
to correlate parameters of metabolic disease, bone remodeling,
and hematopoiesis with MAT volume. Thus, we chose a model
of progressive metabolic dysfunction – mice lacking the extracellular matrix (ECM) protein microfibril-associated glycoprotein-1
(MAGP1).
The ECM is a milieu of structural proteins, proteoglycans,
and adhesive glycoproteins (11). MAGPs are a non-structural
component of the ECM. The biology of this family has been
recently reviewed (12). Briefly, MAGP1 (Mfap2) is broadly
expressed, including both adipose tissue and bone (13, 14),
and typically associates with fibrillin-rich microfibrils.
MAGP1 may also interact with collagen-VI fibers (15).
Characterization of MAGP1-deficient mice (Mfap2−/−) suggests that MAGP1 does not contribute to the mechanical
integrity of its associated ECM fibers (16). Rather, MAGP1
functions as a gatekeeper of signal transduction. A significant
body of evidence has demonstrated that MAGP1 interacts
with ligands of the transforming growth factor beta (TGFβ)
superfamily; sequestering them in the ECM (13, 14, 16, 17).
In mice, MAGP1 deficiency (Mfap2−/−) results in adipocyte
hypertrophy in peripheral white adipose tissue (WAT), diabetes, and reduced bone mass (13, 14). These phenotypes are
progressive, developing with age.
Using the Mfap2−/− model, we demonstrate that MAT expansion occurs concurrent with insulin resistance, not excessive
peripheral adiposity or hyperglycemia. Bone loss in the MAGP1deficient mice occurs without corresponding increases in MAT.
Furthermore, a fivefold increase in MAT in the proximal tibia
does not negatively affect bone marrow (BM) cellularity.

Animals and Diet

Frontiers in Endocrinology | www.frontiersin.org

All animals were C57BL/6 background males, housed in a
pathogen-free animal facility and fed standard chow ad libitum.
MAGP1-deficient mice were generated using C57BL/6-derived
ES cells [Mfap2tm1a(KOMP)Wtsi] purchased from KOMP Repository
(Davis, CA, USA). ES cells were injected into blastocyst from
C57BL/6 donors and transferred into pseudopregnant C57BL/6
females. Offspring were maintained on the Jackson Laboratories
C57BL/6J strain. These mice are a newly derived line and are
therefore different from the Mfap2−/− mice used in previous studies (13, 14, 16, 17). All animals were treated in accordance with
animal protocols approved by the Animal Studies Committee at
Washington University.

Tissue Collection

Tissues were harvested at 2, 6, and 10 months. Mouse fur was
sprayed with 70% EtOH, then gonadal white adipose tissue
(gWAT), and tibias were collected. Tissues were cleaned thoroughly of all contaminants (hair, connective tissue, etc.), then
frozen or stored in 10% neutral buffered formalin.

Insulin Tolerance Test

For insulin tolerance tests (ITTs), mice were fasted for 6 h and
then given an injection of 0.75 U/kg Humulin-R insulin (Lilly,
Indianapolis, IN, USA). Insulin was delivered by intraperitoneal
injection, and tail blood glucose concentration was measured
using Contour strips and meters (Bayer, Whippany, NJ, USA) at
the indicated intervals.

Osmium Staining and Micro-Computed
Tomography

Micro-computed tomography (μCT) was completed on tibias
from 2-, 6-, and 10-month-old mice. Bones were fixed in 10%
neutral buffered formalin and then embedded in 2% agarose gel.
Tibias were scanned at 20 μm voxel resolution using a Scanco μCT
40 (Scanco Medical AG, Zurich, Switzerland) calibrated using a
hydroxyapatite phantom. Measurements of both trabecular and
cortical bones were made based on reported guidelines (18). For
trabecular bone, 50 slices below the growth plate were contoured
to exclude the cortical bone, allowing trabecular bone volume/
tissue volume (BV/TV) and bone mineral density (BMD) to be
determined. For cortical bone, 20 slices – 2 mm proximal to the
tibia–fibula junction were analyzed to determine cortical tissue
mineral density (TMD). A threshold of 175 for trabecular bone
and 260 for cortical bone (on a 0–1000 scale) was maintained.
Note: two 10-month-old Mfap2−/− bones were excluded from
study due to suspected fracture.
Tibias were then decalcified in 14% EDTA for 3 weeks.
Demineralized bones were incubated in a solution containing
1% osmium and 2.5% potassium dichromate for 48 h at room
temperature. After thorough washing (water), tibias were embedded in 1% agarose gel. Osmium stained bones were then scanned
as above, using a Scanco μCT 40, but at 10 μm voxel resolution.
Analysis was performed in the same region as the trabecular
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bone (1,000 μm distal to the growth plate, 100 slices), using a
threshold of 350 (on a 0–1000 scale). Osmium volume (OV) is
quantification of the total OV within the region of interest. OV/
TV is division of the OV by the volume of the marrow cavity
within the same region.

(N418), allophycocyanin (APC)-conjugated CD19 (1D3),
APC-conjugated CD45R/B220 (RA3-6B2), APC-eFluor780conjugated Ly-6G (Gr1, RB6-8C5), and PE-conjugated CD115
(AFS98). Two million live events were collected in the live gate
and analyzed via FlowJo. Gating strategies can be found in
Figure S1 in Supplementary Material.

Flow Cytometry

Statistical Analysis

Blood, spleen, and BM (one each of pelvis bone, femur, and
tibia) were harvested from Jackson Laboratories c57BL/6J
WT and Mfap2−/− mice using standard techniques. Single cell
suspensions were made, and red blood cells were lysed. Blood
cells were counted using a Hemavet. BM and spleen cells were
counted using a Cellometer. Ten million cells were stained and
washed in FACS buffer (PBS, 1% BSA, 0.1% sodium aziade,
and 2 μm EDTA). For monocyte, macrophage, and neutrophil
analyses, cells from each tissue were stained with Brilliant
Violet 421-conjugated F4/80 (BM8), peridinin chlorophyll
protein complex (PerCP)-Cy5.5-conjugated MHC Class II
(M5/114.15.2), phycoerythrin (PE)-Cy7-conjugated CD11c

Statistical comparisons were performed using Graphpad
Prism® (GraphPad Software, Inc., La Jolla, CA, USA). In
Figures 1–3, with the exception of panel 2D, comparisons
between wild-type (WT) and Mfap2−/− mice at each time point
and over time within groups (WT or Mfap2−/−) were performed
using a regular two-way ANOVA with Holm–Sidak correction
for multiple comparisons. For the ITTs in panel 2D, repeated
measures two-way ANOVA with Sidak’s correction was used.
In Figures 4 and 5, results were compared with a two-tailed
t-test. Comparisons with a P-value ≤0.05 were considered
statistically significant.

Figure 1 | MAT expansion in Mfap2−/− mice. (A) Micro-computed tomography (μCT) visualization of osmium stained lipid within the decalcified proximal tibia.
(B,C) Region analyzed for osmium volume (OV) was 1 mm distal to the growth plate. OV/TV is osmium volume divided by the marrow cavity volume in the same
region. Mean ± SEM; Sample sizes for WT and Mfap2−/− mice, respectively: 2 months: n = 8, 8; 6 months: n = 6, 8; and 10 months: n = 8, 6. Statistical significance
at each time point and within groups (WT or Mfap2−/−) over time was determined by two-way ANOVA with Holm–Sidak’s correction for multiple comparisons
(*p ≤ 0.05, a = significant relative to 2 months of same genotype, and b = significant relative to 6 months of same genotype). Scale bar is 100 μm. Note: two
10-month-old Mfap2−/− bones were excluded from study due to suspected fracture.
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Figure 2 | Characterization of metabolic disorder in Mfap2−/−mice. (A) Gonadal white adipose tissue (WAT) was harvested at 2 months (n = 10, 8), 6 months
(n = 6, 8), and 10 months (n = 8, 8). (B) Total body weight at 2 months (n = 10, 8), 6 months (n = 7, 9), and 10 months (n = 8, 8). (C) Fasted (6 h) blood glucose
concentration at 2 months (n = 10, 8), 6 months (n = 6, 8), and 10 months (n = 8, 8). (D) Insulin sensitivity results at 2 months (n = 10, 8), 6 months (n = 5, 8), and
10 months (n = 8, 8). Blood glucose data were normalized to time point 0 (before insulin injection). Mean ± SEM; statistical significance in (A–C) at each time point
and within groups (WT or Mfap2−/−) over time was determined by two-way ANOVA with Holm–Sidak’s correction for multiple comparisons. Statistical significance in
(D) was determined by repeated-measured two-way ANOVA with Sidak’s correction (*p ≤ 0.05, a = significant relative to 2 months of same genotype, and
b = significant relative to 6 months of same genotype). Sample sizes shown above are for WT and Mfap2−/− mice, respectively.

RESULTS

with previous results, 2-month-old Mfap2−/− mice had only a
modest 15% increase in white fat (as measured by gonadal fat
pad mass, Figure 2A). However, by 6 months, Mfap2−/− mice had
a 2.7-fold increase in fat mass, relative to WT mice. Extending
our study to 10 months of age, we found that the differential
in fat mass stabilizes, indicated by a 1.8-fold increase Mfap2−/−
gonadal fat pad mass relative to WT mice. Total body weight
reinforced this finding (Figure 2B). Mfap2−/− body weight was
insignificantly increased at 2 months, but a significant (17%)
increase in Mfap2−/− weight was found at 6 months. Similar
to the fat mass measurement, the weight differential between
WT and Mfap2−/− mice stabilized, remaining increased by 17%
relative to baseline, at 10 months. Six-hour fasting blood glucose
was significantly elevated in Mfap2−/− mice by 2 months (12%,
Figure 2C). By 6 months, fasted blood glucose was 63% higher
in Mfap2−/− mice relative to WT mice. However, by 10 months,
there was only a 35% increase in Mfap2−/− blood glucose
relative to WT. To characterize metabolic function, ITTs were
performed on WT and Mfap2−/− mice at all ages (Figure 2D).
In contrast to fat mass, body weight, and fasting blood glucose,
insulin resistance did not reach statistical significance until
the Mfap2−/− mice were 10-month old. Thus, Mfap2−/− mice

Pathologic MAT Expansion in
Mfap2−/− Mice

To compare parameters of metabolic disease with MAT expansion, a longitudinal study was performed in MAGP1-deficient
(Mfap2−/−) mice that are susceptible to metabolic syndrome.
Marrow adiposity was determined by μCT imaging of osmium
stained lipid within the proximal tibia (Figure 1A). Quantification
of total marrow lipid OV and OV normalized to total marrow cavity volume (OV/TV) is shown in Figures 1B,C. Marrow adiposity
was found to be indistinguishable in either young (2 months) or
adult (6 months) Mfap2−/− mice, relative to WT mice. However,
aged 10-month-old Mfap2−/− mice displayed a fivefold increase
in marrow lipid (OV and OV/TV) relative to WT animals. WT
C57BL/6 mice have only a modest, statistically insignificant,
increase (54%) in MAT between 6 and 10 months.

Characterization of Metabolic Dysfunction
in Mfap2−/− Mice

Previously, we demonstrated that MAGP1 deficiency results in
excess adiposity and reduced bone mass (13, 14, 16). Consistent
Frontiers in Endocrinology | www.frontiersin.org
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Figure 3 | Skeletal changes in Mfap2−/− mice. Tibias were harvested at 2, 6, and 10 months. Micro-comupted tomography was used to determine the ratio of
bone volume to total volume (BV/TV) and bone mineral density (BMD/TMD). (A–C) For trabecular bone, 1 mm distal to the growth plate was analyzed. (D) For
cortical bone, tissue mineral density (TMD) was determined by contouring 400 μm located 2 mm proximal to the tibia–fibula junction. Sample size for WT and
Mfap2−/− mice, respectively, are 2 months n = 8, 8; 6 months n = 6, 8; and 10 months n = 8, 6. Mean ± SEM; statistical significance at each time point and within
groups (WT or Mfap2−/−) over time was determined by two-way ANOVA with Holm–Sidak’s correction for multiple comparisons (*p ≤ 0.05, a = significant relative to
2 months of same genotype, and b = significant relative to 6 months of same genotype). Scale bar is 100 μm. Note: two 10-month-old Mfap2−/− bones were
excluded from study due to suspected fracture.

are severely hyperglycemic by 6 months in age, but not insulin
resistant until 10 months.

analysis was performed using the same region of interest analyzed
for MAT (Figures 3B,C). Reduced trabecular bone volume (BV/
TV) and BMD were detectable in Mfap2−/− mice by 2 months.
Aging of WT mice from 6 to 10 months was associated with
statistically significant reductions in trabecular bone volume
(−32%, Figure 3B) and mineral density (−19%, Figure 3C),
but not a statistically significant increase in MAT (Figure 1C).
During this time, Mfap2−/− mice had a 22% reduction in BV/

Relationship between MAT Expansion and
Bone Mass

Tibial bone morphology was assessed by μCT prior to osmium
staining for MAT quantification (Figure 3A). Trabecular bone

Frontiers in Endocrinology | www.frontiersin.org
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Figure 4 | MAT expansion and hematopoiesis. To address the consequence of pathologic MAT expansion on hematopoiesis, the cellularity of the (A) bone
marrow, (B) spleen, and (C) blood [white blood cells (WBCs)] were measured at 10 months. Sample size for WT and Mfap2−/− mice, respectively, are n = 8, 8 (A,B)
or n = 8, 7 (C). Mean ± SEM; Student’s t-test was done for single comparison (*p ≤ 0.05 and ***p ≤ 0.001).

TV (Figure 3B), but a 5.2-fold increase in MAT volume (OV/
TV, Figure 1C). Cortical bone density was maintained during
aging and unchanged by MAT accumulation (Figure 3D). In
fact, cortical BMD was highest at 10 months in both WT and
Mfap2−/− mice. Additional μCT indices of bone structure can be
found in Tables S1 and S2 in Supplementary Material.

correlates with increased marrow adiposity (6). The rapid change
in adiposity impedes our understanding of whether changes in
peripheral adipose tissue lipid storage shift lipids to the marrow,
or if metabolic changes such as insulin resistance contribute to
MAT expansion. To address this question, we performed a longitudinal study of mice predisposed to excess, age-associated fat
accumulation without dietary intervention.
Microfibril-associated glycoprotein-1 is a matricellular
protein that associates with ECM structures but does not contribute to their biophysical properties. Instead, MAGP1 affords
fibrillar structures the capacity to regulate signal transduction
by tethering growth factors to the ECM [reviewed in Ref. (12)].
MAGP1 is expressed in adipose tissue. MAGP1 deficiency in
mice (Mfap2−/−) causes adipocyte hypertrophy in peripheral
WAT, which contributes to obesity and then insulin resistance
(13). MAGP1 is also highly expressed by osteoblasts in the bone.
Loss of MAGP1 in vivo leads to increased osteoclast number and
reduced bone mass (14). In this study, MAT expansion did not
occur coincident with bone loss or excess peripheral adiposity in
Mfap2−/− mice; osteopenia was detectable by 2 months and excess
adiposity by 6 months in Mfap2−/− mice whereas pathologic MAT
expansion was not detectable until 10 months of age. This suggests
that MAGP1 deficiency in bone is sufficient to cause abnormal
bone remodeling but is unlikely to be mediating the changes in
MAT. Instead, MAT expansion coincided with insulin resistance
in Mfap2−/− mice. Our findings are of importance because they
address three confounding factors of MAT biology: the mechanisms that drive MAT expansion, the relationship between MAT
expansion and bone loss, and whether MAT is detrimental to
hematopoiesis.
The coincidence of MAT expansion with insulin resistance
suggests that insulin may limit MAT adipocyte size or number.
Insulin signaling in marrow adipocytes has not been reported,
thus, we cannot comment on insulin’s direct action on lipid
storage or adipogenesis in these specialized cells. However, the
pathophysiology of insulin resistance could induce a secondary complication (e.g., hyperlipidemia) that drives subsequent

MAT Expansion and Hematopoiesis

To address the impact of pathologic MAT expansion on hematopoietic function, we measured the cellularity of the BM and
spleen as well as the number of circulating white blood cells
(WBCs) at 10 months of age. BM cellularity was not significantly
reduced in Mfap2−/− mice, despite the fivefold increase in MAT
(Figure 4A). However, spleen cellularity was slightly elevated
and WBC count was decreased in Mfap2−/− mice (Figures 4B,C).
To further investigate these findings, flow cytometry was used
to assess hematopoietic lineage distribution. Within the BM of
Mfap2−/− mice, there was a modest increase in macrophages,
myeloid-derived dendritic cells (MDCs), and B-cells (+61,
+78, and +18%, respectively) and a corresponding decrease in
neutrophils relative to WT mice (−13%) (Figure 5A). In the
spleen, there was a significant increase in MDCs (+250%) and
decrease in neutrophils (−72%), with a trend to increased B-cells
(Figure 5B). Finally, in the blood, we observed an increase in
monocytes (+216%) and a modest decrease in B-cells (−15%) in
Mfap2−/− mice (Figure 5C).

DISCUSSION
Once viewed as inert, space-filling structures, BM adipocytes are
now recognized as metabolically active cells with the potential
to influence bone remodeling and hematopoiesis. The relationship between MAT volume and peripheral fat mass has been
addressed previously (9, 10). In rodents, weight gain resulting
from HFD feeding is associated with significant MAT expansion.
However, extreme peripheral fat loss due to caloric restriction also

Frontiers in Endocrinology | www.frontiersin.org
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Figure 5 | Neutrophil, macrophage, myeloid-derived dendritic cell, monocyte, and B cell frequency within the (A) bone marrow, (B) spleen, and (C)
blood at 10 months. Neutrophils: B220−, Gr1+. Macrophage: B220−, Gr1−, MHCII+, F4/80+, and CD11c−. Dendritic cell: B220−, Gr1−, MHCII+, F4/80−, and
CD11c+. Monocyte: B220−, Gr1−, and F4/80+. Sample sizes for WT and Mfap2−/− mice, respectively, are n = 8 and 8. Mean ± SEM; Student’s t-test was done for
single comparison (*p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001).

MAT expansion. Insulin is a potent inhibitor of lipolysis, the
breakdown of triglyceride stores, in traditional white adipocytes.
Insulin resistance is therefore associated with elevated circulating
free fatty acids (FFA) and excess energy storage in atypical sites

Frontiers in Endocrinology | www.frontiersin.org

(e.g., muscle and liver) (19). It is possible that marrow adipocytes
respond to elevated FFA associated with insulin resistance by
storing them as triglycerides. Rodent models of type 1 diabetes
(T1DM) also display significant MAT accumulation (20–22),
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within Mfap2−/− BM. However, the implications of this finding
are unclear. Future studies are needed to examine the remodeling
of the MAT adipocyte niche in response to obesity.
The goal of this project was to determine the association
between pathologic MAT expansion and peripheral indicators
of metabolic dysfunction without the use of modified diet. We
also addressed the relationship between MAT expansion and
bone mass, and the consequence of pathologic MAT expansion
on hematopoiesis. We found that MAT volume was not linked
directly to peripheral fat accumulation and, instead, coincided
with insulin resistance. Furthermore, we found that bone loss
occurred, regardless of MAT expansion, in Mfap2−/− relative to
WT at all ages. Lastly, we show that MAT expansion is associated
with modest alterations in basal hematopoiesis, including a shift
from granulopoiesis to B lymphopoiesis.

providing a second example of perturbed insulin signaling associating with hyperlipidemia and MAT expansion.
The relationship between marrow adiposity and bone mass is
highly debated. Published reports have shown that MAT expansion can coincide with increased, reduced, or unchanged bone
volume (9, 10, 23–27).
Substantial in vitro evidence demonstrates that adipocytes and
osteoblasts arise from the same mesenchymal progenitor. If true,
maturation of mesenchymal stem cells through the adipocyte lineage should be at the expense of the osteoblast lineage. However,
in vivo evidence is conflicting. Specifically, lineage tracing of marrow adipocytes has demonstrated that the osteoblasts are derived
from a Gremlin-1 positive mesenchymal progenitor cell, but these
Gremlin-1 positive cells do not differentiate into adipocytes (28).
This would allow osteoblast cell numbers to exist independent of
marrow adipocyte number. The marrow cavity is also a relatively
defined space, and it would, therefore, seem that expansion of MAT
must occur at the expense of something else, such as bone. Our
study supports a disconnection between MAT volume and bone
volume. When WT and Mfap2−/− mice age from 6 to 10 months,
there is an increase in MAT and decrease in BV/TV. However,
loss of trabecular BV/TV from 6 to 10 months is actually greater
in WT mice, despite Mfap2−/− mice having a greater accrual of
MAT. Specifically, in WT mice, BV/TV loss is 32% and MAT
volume increases 54%; however, MAT volume in Mfap2−/− mice is
increased 530% but BV/TV is decreased only 22%.
Marrow adipocytes are considered as members of the hematopoietic niche. Marrow adiposity and hematopoiesis have been
studied in the context of marrow ablation by irradiation and
chemotherapy. From these studies, it was concluded that the filling of the marrow with fat impedes marrow reconstitution and
hematopoiesis (29–31). The current study investigated the consequence of pathologic MAT expansion on existing hematopoietic
cells (not reconstitution). We found a significant reduction in circulating WBCs and a small increase in spleen cellularity, indicators
of BM failure and extramedullary hematopoiesis. Further study is
needed to determine whether MAT expansion in this model leads
to a loss of functional hematopoietic stem cells. Unexpectedly,
however, total BM cellularity was unchanged. This may be due
to shifts in marrow composition to favor loss of fluid space and
vascular tone with MAT expansion to allow subsequent preservation of hematopoiesis. We also examined whether fat expansion
within the marrow would cause a recruitment (or retention) of
macrophages. Macrophages are recruited to peripheral adipose
tissue to allow remodeling of adipose tissue during expansion,
and because of this, obesity is linked to fat inflammation (32).
Indeed, we found a slight increase in macrophage frequency
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